OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Treatment of Dementia

Submission Deadline: November 30, 2019 (Open) Submit Now

Guest Editor

Michael Fossel, MD, PhD

1. President of Telocyte (http://www.telocyte.com), Grand Rapids, MI 49503, USA
2. Retired Clinical Professor of Medicine, Michigan State University, Ada, MI 49301, USA

Website | E-Mail

Research Interests: human aging; telomeres; telomerase therapy; age-related diseases; Alzheimer's disease

About This Topic

According to the recent report by the World Health Organization (WHO), as for the global dementia prevalence, the number of people with dementia in the world is now approximately 35.6 million. It is forecasted to increase to 39 million by 2050. Dementia is increasing worldwide, but more than half (58%) of the patients are concentrated in low- and middle-income countries, and this percentage will rise to more than 70% by 2050. The total cost of treating dementia and social loss worldwide is over 50 trillion yen (US $604 billion) per year. In this special feature, we will introduce efforts all over the world, and would like to outline the latest treatment of dementia in the world, in addition to pharmaceutical approaches, control over insulin resistance, diets, exercise, communication with others, mindfulness and other psychological approaches.

Planned Papers

Title: Palliative Care in Dementia- when is the appropriate time to intiate?
Authors: SC Lim and Edward Poon

Title: Forgotten: Narratives of Age-Related Dementia and Alzheimer’s Disease in Canada by Marlene Goldman, Book Review
Author: Julia Henderson, PhD

Title: Usefulness of the Long-Term Intermittent Hypoxic - Hyperoxic Training (IHHT) in Alzheimer’s type Dementia Treatment: Two Case Studies
Author: Arkadi F. Prokopov

Title: Parting with the concept of Alzheimer´s disease in senium.
Authors: Kalvach P., Vogner M.

Title: Multimodal Treatment for Dementia: Collaborative Research with the NHS, Functional Medicine and Lifestyle Change
Authors: Dr. Garuth Chalfont, Dr. Jane Simpson, Dr. Sarah Davies, Dr. Leigh Willoughby, Dr. David Morris, Professor Christine Milligan

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!


Open Access Review

New Horizons in Alzheimer Research from Amyloid and Beyond

Received: 01 December 2019;  Published: 29 April 2020;  doi: 10.21926/obm.geriatr.2002116


The Amyloid and Tau Hypothesis of Alzheimer’s disease once thought to be the key have shown marginal results but are bolstered by the recent revival of the Aducanumab study and some positive data on some anti-Tau drugs. It still behoves us to look at other mechanisms which include whole blood transfusions, an Epigenetic approach, a-derivativ [...]
Open Access Perspective

Target Tau, not Amyloid, to Prevent and Treat Alzheimer’s Disease

Received: 27 November 2019;  Published: 04 February 2020;  doi: 10.21926/obm.geriatr.2001103


In this article I wish to put the case for a change of emphasis in the approach to finding a prevention/treatment for Alzheimer’s disease from a focus on beta amyloid to one on tau. In particular, I make the case for aiming to prevent the spread of abnormal tau from the medial temporal lobe to widespread areas of association cortex that [...]
Open Access Book Review

Review of: Forgotten: Narratives of Age-Related Dementia and Alzheimer’s Disease in Canada. By Marlene Goldman. McGill-Queen’s Press, 2017

Received: 05 November 2019;  Published: 17 January 2020;  doi: 10.21926/obm.geriatr.2001101


Open Access Original Research

Intranasal Insulin in Alzheimer’s Disease: A Pragmatic Account

Received: 15 March 2019;  Published: 13 August 2019;  doi: 10.21926/obm.geriatr.1903069


Pragmatic competence includes the capacity to express illocutionary force and successfully achieve perlocutionary effects, in order to guarantee fully functional communication exchanges. Improved pragmatic competence in patients has been found in patients with Mild Cognitive Impairment (MCI) and early to moderate Alzheimer’s Disease (AD [...]
Open Access Review

The Value Given and Presupposed in Person-Centred Dementia Care

Received: 08 April 2019;  Published: 13 August 2019;  doi: 10.21926/obm.geriatr.1903068


Thirty years ago, Tom Kitwood proposed a change in the care of people with dementia, from ‘warehousing’ to ‘person-centred care’. The change had noticeable benefits for those with dementia. Kitwood set out his presuppositions for this change. For example, Kitwood understood personhood as the standing or status bestowed on one human [...]
Open Access Review

Parting with the Concept of Alzheimer’s Disease in Senium

Received: 30 March 2019;  Published: 08 July 2019;  doi: 10.21926/obm.geriatr.1903060


Our understanding of the mental deterioration associated with old-age have undergone a number of changes over the past two centuries and have spurred major scientific debates. In the 19th century, this disorder was still considered to be an inevitable feature of aging. The dawn of the 20th century offered a histological explanation for preseni [...]
Open Access Review

Treating Dementia Early: Limiting Cellular Damage in Brain Tissue

Received: 27 December 2018;  Published: 17 June 2019;  doi: 10.21926/obm.geriatr.1902057


Much evidence has been published which indicates that microvascular endothelial dysfunction, due to cerebrovascular risk factors (e.g., atherosclerosis, hypertension, obesity, diabetes, smoking, aging), precedes cognitive decline in Alzheimer's disease and contributes to its pathogenesis. By incorporating appropriate drug(s) into biomimetic [...]
Open Access Case Report

Daily Observations of Preserved Cognition and Quality of Life after Multiple Therapies for Postmortem-Verified Severe Alzheimer’s

Received: 15 February 2019;  Published: 18 April 2019;  doi: 10.21926/obm.geriatr.1902048


Abstract Background: Cognitive abilities in Alzheimer’s Disease are usually examined by formal tests conducted in a laboratory or facility. Such tests are useful for determining the severity of the disease but do not indicate the types of cognition exhibited in the daily lives of patients. This study shows cognitive preservation in dail [...]
Open Access Review

Does Dementia Increase the Risk of Dental Decay?

Received: 09 January 2019;  Published: 21 March 2019;  doi: 10.21926/obm.geriatr.1901040


The amount of patients who suffer with dementia is set to rise with an ageing population living longer. As well as living longer, patients will be retaining their natural teeth longer and will be less reliant on dentures. From both the current evidence available in the literature, and anecdotally from clinicians experienced in treating [...]
Open Access Research Article

Key Dimensions of Therapeutic Lies in Dementia Care: A New Taxonomy

Received: 12 December 2018;  Published: 11 February 2019;  doi: 10.21926/obm.geriatr.1901032


Background: Research suggests that the use of lies and deception is prevalent within dementia care settings, despite ongoing debates raised about the ethics of this approach. There has been increasing exploration of when and why deceptive practices should be used, but the lack of clarity as to what constitutes a lie has caused difficulty [...]
Open Access Opinion

Do Social Isolation and Loneliness Kill People with Alzheimer's Disease?

Received: 04 October 2018;  Published: 26 November 2018;  doi: 10.21926/obm.geriatr.1804021


Patients with AD have shortened life expectancy than the general older population is well established. Loneliness may be another risk factor to consider if we wish to understand and improve the premature mortality of AD.